The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Ryzneuta efbemalenograstim alfa Additional monitoring | Fisiopharma S.r.l. | 🇪🇺 EU 2024-03-21 | Order → | |
| Dabigatran etexilate Teva (previously Dabigatran etexilate Leon Farma) dabigatran etexilate Generic | Teva GmbH | Venous Thromboembolism; Arthroplasty, Replacement | 🇪🇺 EU 2024-02-19 | Order → |
| Ibuprofen Gen.Orph ibuprofen Generic | Gen.Orph | Ductus Arteriosus, Patent | 🇪🇺 EU 2024-02-16 | Order → |
| Pomalidomide Viatris pomalidomide Generic | Viatris Limited | Multiple Myeloma | 🇪🇺 EU 2024-02-16 | Order → |
| Velsipity etrasimod Additional monitoring | Pfizer Europe MA EEIG | Colitis, Ulcerative | 🇪🇺 EU 2024-02-16 | Order → |
| Vlustozik (previously Ibuprofen Gen.Orph) ibuprofen Generic | Gen.Orph | Ductus Arteriosus, Patent | 🇪🇺 EU 2024-02-16 | Order → |
| Casgevy exagamglogene autotemcel OrphanPRIMEATMP | Vertex Pharmaceuticals (Ireland) Limited | beta-Thalassemia; Anemia, Sickle Cell | 🇪🇺 EU 2024-02-09 | Order → |
| Mevlyq eribulin Generic | YES Pharmaceutical Development Services GmbH | Breast Neoplasms; Liposarcoma | 🇪🇺 EU 2024-02-09 | Order → |
| Skyclarys omaveloxolone OrphanAdditional monitoring | Biogen Netherlands B.V. | Friedreich Ataxia | 🇪🇺 EU 2024-02-09 | Order → |
| Omjjara momelotinib OrphanAdditional monitoring | GlaxoSmithKline Trading Services Limited | Splenomegaly; Myeloproliferative Disorders | 🇪🇺 EU 2024-01-25 | Order → |
| Azacitidine Kabi azacitidine Generic | Fresenius Kabi Deutschland GmbH | Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute | 🇪🇺 EU 2024-01-05 | Order → |
| Krazati adagrasib ConditionalAdditional monitoring | Bristol-Myers Squibb Pharma EEIG | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2024-01-05 | Order → |
| Naveruclif paclitaxel Generic | Accord Healthcare S.L.U. | Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2024-01-05 | Order → |
| Rimmyrah ranibizumab BiosimilarAdditional monitoring | Qilu Pharma Spain S.L. | Wet Macular Degeneration; Macular Edema; Diabetes Complications; Myopia, Degenerative; Choroidal Neovascularization | 🇪🇺 EU 2024-01-05 | Order → |
| Rystiggo rozanolixizumab OrphanAdditional monitoring | UCB Pharma | Myasthenia Gravis | 🇪🇺 EU 2024-01-05 | Order → |
| Spexotras trametinib Orphan | Novartis Europharm Limited | Glioma | 🇪🇺 EU 2024-01-05 | Order → |
| Uzpruvo ustekinumab Biosimilar | Stada Arzneimittel AG | Psoriasis; Arthritis, Psoriatic; Crohn Disease; Colitis, Ulcerative | 🇪🇺 EU 2024-01-05 | Order → |
| Rezzayo rezafungin OrphanAdditional monitoring | Mundipharma GmbH | Candidiasis; Candidiasis, Invasive | 🇪🇺 EU 2023-12-22 | Order → |
| Loargys pegzilarginase OrphanExceptional circumstancesAdditional monitoring | Immedica Pharma AB | Hyperargininemia | 🇪🇺 EU 2023-12-15 | Order → |
| Agamree vamorolone OrphanAdditional monitoring | Santhera Pharmaceuticals (Deutschland) GmbH | Muscular Dystrophy, Duchenne | 🇪🇺 EU 2023-12-14 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.